Skip to main content

How is Arzerra administered and how long to work?

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 21, 2023.

Official answer

by Drugs.com

Arzerra (ofatumumab) is administered by an intravenous infusion. It is diluted into a sterile bag of 1000mL sodium chloride for intravenous infusion which is then hung up and the infusion administered into one of your veins via an intravenous line. How long the infusion takes depends on your stage of Chronic Lymphocytic Leukemia (CLL) and if you have had treatment before, but initially Arzerra is usually administered over about 6 hours. The time of the infusion may be shortened, depending on how well you tolerate Arzerra.

How long does it take Arzerra to work?

Arzerra starts working right away but it may take several months before a difference is noted in the progression of your cancer. Trials investigating Arzerra for CLL looked at progression free survival and reported:

  • For patients assigned Arzerra with chlorambucil their previously untreated CLL did not worsen for a median of 22 months, compared to 13 months to those assigned chlorambucil alone
  • 82% of patients had a response including 12% whose cancer went away
  • The responses lasted for an average of 22 months.

In those people whose CLL had relapsed:

  • The disease did not get worse for an average of 29 months in those assigned Arzerra plus fludarabine plus cyclophosphamide, compared to 19 months to those assigned just fludarabine and cyclophosphamide
  • 84% of patients had a response including 29% whose cancer went away
  • Patients lived for an average of 56 months.
References

Read next

What is Arzerra used for and how does it work?

Arzerra (ofatumumab) is approved by the FDA to treat patients with chronic lymphocytic leukemia (CLL), a type of slowly progressing cancer in your blood and bone marrow. It's an antibody therapy that works with the immune system to attack and destroy cancerous CD20-positive B cells. Continue reading

What is the success rate of Rituxan (rituximab) in patients with blood cancers?

In patients with hematological or blood cancers, including non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), Rituxan’s success is measured in a number of ways. It is measured by looking at how long patients responded to treatment (median duration of response), how long they live without their disease progressing (progression-free survival) and how many patients respond to treatment (response rate).

Rituxan treatment improves outcomes in certain patients with NHL. Adding Rituxan alongside standard therapies enhances the response patients have to treatment and improves overall outcomes, including increasing the time patients live for without experiencing a progression of their disease.

Rituxan helps to improve overall survival in certain patients with CLL and also helps to increase the time patients live for without experiencing disease progression. Adding Rituxan alongside standard therapy enhances the response patients have to therapy. Continue reading

Is Venclexta (venetoclax) chemotherapy?

Venclexta (venetoclax) is a targeted treatment rather than a type of chemotherapy. Chemotherapy is defined as a drug treatment that kills fast-growing cells in your body. Venclexta works by binding to a specific protein called BCL-2 which is overexpressed on cancerous cells in people with cancers such as AML and CLL. By binding to this protein Venclexta kills cancerous CLL and AML lymphocytes, in preference to other fast-growing cells. Continue reading

Related medical questions

Drug information

Related support groups